# Coherus Oncology, Inc. (CHRS)

> Source: Nexqual · https://nexqual.com/CHRS · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Coherus Oncology, Inc. (CHRS), nexqual.com/CHRS" · informational, not investment advice.

**Price:** USD 1.07 (+1.90% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.05 · day 1.03–1.09 · 52w 0.97–2.62 · market cap $165M · NGM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 7.75 (range 4–10).
- Total return with dividends: 1Y -37.4% vs S&P 500 +18.1%; 5Y -93.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.21, revenue estimate $16.0M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 7.75 (low 4, high 10).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | Guggenheim | Target lowered | Buy | $12 → $10 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -37.4% | -93.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -37.5% | -42.4% |
| Volatility (annualized) | 79.5% | 92.5% |
| Max drawdown | -59.8% (Jan 2026→Oct 2026) | -96.1% (Nov 2021→Oct 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/CHRS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt